Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Q2W Vectibix® achieved statistically significant non-inferiority to QW cetuximab for overall survival (OS) in patients with chemorefractory wild-type KRAS* metastatic colorectal cancer (mCRC)1†

(HR = 0.97; 95% Cl: 0.84-1.11).

The ASPECCT clinical study design: a phase 3, open-label, randomized, non-inferiority study of Vectibix® versus cetuximab1,2 ‡

Primary endpoint1,2

  • Overall survival (OS) assessed for non‑inferiority1,2

Key secondary endpoints1,2

  • Investigator-assessed progression-free survival (PFS)1,2
  • Objective response rate (ORR)1,2

Patient characteristics1,2

  • Patients with chemorefractory wild-type (WT)
    KRAS metastatic colorectal cancer1,2
  • No prior anti-EGFR therapy2
  • ECOG performance status 0–22
  • Patients received prior treatment with irinotecan, oxaliplatin, and a thymidylate synthase inhibitor1
Rotate screen for larger view

ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; mCRC = metstatic colorectal cancer; QW = weekly; Q2W = every two weeks.

ASPECCT = A Study of Panitumumab Efficacy and Safety Compared to CeTuximab.

*Exon 2 in codons 12 or 13.1

The criterion for non-inferiority was for Vectibix® to retain at least 50% of the OS benefit of cetuximab based on OS hazard ratio of 0.55 from the NCIC CTG CO.17 study related to best supportive care (BSC).


Study results

  • Q2W Vectibix® achieved statistically significant non-inferiority to QW cetuximab for overall survival (OS) in patients with chemofractory wild-type (WT) KRAS metastatic colorectal cancer (mCRC) (HR = 0.97%; 95% Cl: 0.84–1.11)1,2
Rotate screen for larger view

Incidence of selected adverse events (all grades)2

Vectibix® cetuximab
All AEs 98% 98%
Infusion reaction 3% 14%
Skin and subcutanous tissue 87% 87%
Hypomagnesemia 27% 18%
Rotate screen for larger view

AE = adverse event.

Site Map
×